Tumor ADC value predicts outcome and yields refined prognostication in uterine cervical cancer

Pelvic MRI is essential for evaluating local and regional tumor extent in uterine cervical cancer (CC). Tumor microstructure captured by diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) markers may be closely linked to prognosis in CC.Purpose To explore whether primary tumor ADC markers predict survival in CC.Material and methods CC patients (n = 179) diagnosed during 2009-2020 with MRI-assessed primary maximum tumor<sub>size</sub> ≥ 2 cm were included in this retrospective single-center study. Two radiologists read all MRIs independently, measuring mean tumor ADC values in manually drawn regions of interest (ROIs) and mean tumor ADC (tumor<sub>ADCmean</sub>) from five measurements for the two readers was used. ADC from ROIs in the myometrium (myometrium<sub>ADC</sub>), cervical stroma (cervix<sub>ADC</sub>), and bladder (bladder<sub>ADC</sub>) were used to calculate ADC ratios. ADC markers were explored in relation to the International Federation of Gynecology and Obstetrics (FIGO) (2018) stage, disease-specific survival (DSS), and recurrence/progression-free survival (RPFS).Results Inter-reader agreement for all ADC measurements was high (ICC:0.59-0.79). Low tumor<sub>ADCmean</sub> predicted advanced FIGO stage (P = 0.04) and reduced DSS (hazard ratio (HR): 0.96, P < 0.001; AIC: 441). Myometrium<sub>ADC</sub>/tumor<sub>ADCmean</sub> yielded the best Cox regression fit (AIC = 430) among all tumor ADC markers. Patients with high myometrium<sub>ADC</sub>/tumor<sub>ADCmean</sub> had significantly reduced 5-year DSS for FIGO stage I, II, and III (P = 0.01, 0.004, and 0.02, respectively) and tended to the same for FIGO IV (P = 0.22).Conclusion Low tumor<sub>ADCmean</sub> predicted reduced DSS in CC. High myometrium<sub>ADC</sub>/tumor<sub>ADCmean</sub> was the strongest ADC predictor of poor DSS and a marker of high-risk phenotype independent of FIGO stage.

Authors

Institutions

Publication Details

Journal
Cancer Imaging
Published
2025-02-28
DOI
https://doi.org/10.1186/s40644-025-00828-6
Citations
4
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
8.23

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumor ADC value predicts outcome and yields refined prognostication in uterine cervical cancer

Kari S. Wagner‐Larsen, David Forsse, Kathrine Woie, Camilla Krakstad et al.
4 citations
Cancer Imaging
Endometrial and Cervical Cancer Treatments
8.23
article

Tumor ADC value predicts outcome and yields refined prognostication in uterine cervical cancer

Kari S. Wagner‐Larsen, David Forsse, Kathrine Woie, Camilla Krakstad, Jone Trovik, Ingfrid S. Haldorsen, Bjørn I. Bertelsen, Njål Lura, Frank Riemer, Kristine E. Fasmer, Mari K. Halle, Øyvind Salvesen, Stian Ryste
article en
4 citations

Abstract

Pelvic MRI is essential for evaluating local and regional tumor extent in uterine cervical cancer (CC). Tumor microstructure captured by diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) markers may be closely linked to prognosis in CC.Purpose To explore whether primary tumor ADC markers predict survival in CC.Material and methods CC patients (n = 179) diagnosed during 2009-2020 with MRI-assessed primary maximum tumor<sub>size</sub> ≥ 2 cm were included in this retrospective single-center study. Two radiologists read all MRIs independently, measuring mean tumor ADC values in manually drawn regions of interest (ROIs) and mean tumor ADC (tumor<sub>ADCmean</sub>) from five measurements for the two readers was used. ADC from ROIs in the myometrium (myometrium<sub>ADC</sub>), cervical stroma (cervix<sub>ADC</sub>), and bladder (bladder<sub>ADC</sub>) were used to calculate ADC ratios. ADC markers were explored in relation to the International Federation of Gynecology and Obstetrics (FIGO) (2018) stage, disease-specific survival (DSS), and recurrence/progression-free survival (RPFS).Results Inter-reader agreement for all ADC measurements was high (ICC:0.59-0.79). Low tumor<sub>ADCmean</sub> predicted advanced FIGO stage (P = 0.04) and reduced DSS (hazard ratio (HR): 0.96, P < 0.001; AIC: 441). Myometrium<sub>ADC</sub>/tumor<sub>ADCmean</sub> yielded the best Cox regression fit (AIC = 430) among all tumor ADC markers. Patients with high myometrium<sub>ADC</sub>/tumor<sub>ADCmean</sub> had significantly reduced 5-year DSS for FIGO stage I, II, and III (P = 0.01, 0.004, and 0.02, respectively) and tended to the same for FIGO IV (P = 0.22).Conclusion Low tumor<sub>ADCmean</sub> predicted reduced DSS in CC. High myometrium<sub>ADC</sub>/tumor<sub>ADCmean</sub> was the strongest ADC predictor of poor DSS and a marker of high-risk phenotype independent of FIGO stage.

Cancer ImagingVol. 25(1)
Norwegian University of Science and Technology (NO), Haukeland University Hospital (NO), University of Bergen (NO)
Trond Mohn stiftelse, Norges Forskningsråd, Helse Vest Regionalt Helseføretak
No poverty
Openalex Percentile: Top 3%
Endometrial and Cervical Cancer Treatments
8.23
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.